Insights

What’s up with the Mesoblast (ASX:MSB) share price?

The Mesoblast Limited (ASX: MSB) share price was falling again today. Let’s look further into what’s been happening for the biotech company.
The post What’s up with the Mesoblast (ASX:MSB) share price? appeared first on The Motley Fool Australia. –

medical asx share price represented by doctor looking up at question marks

Mesoblast Limited (ASX: MSB) shares were dropping again today and, with no news from the company, the question is why? By the market’s close, the Mesoblast share price was trading at $2.39, down 3.24% from yesterday’s close. This compares to the S&P/ASX 200 Index (ASX: XJO), which was up 0.5% today.

The stem cell focused biotech company is listed on both the ASX and Nasdaq and its ASX share price has fallen by 51.32% over the last 6 months.

Let’s look further into what’s been happening for Mesoblast.

Recent share price fluctuations

The Mesoblast share price had an eventful 2020, which included steep falls in December after trials for some of the company’s new products delivered disappointing results.

On 15 December, the company announced that while its phase 3 trial of REVASCOR for advanced chronic heart failure showed good results, it did not achieve the objectives of the trial. This less than pleasing news saw Mesoblast shares plummet by more than 45% in one day.

Then, only days later, Mesoblast announced its randomised controlled trial of remestemcel-L in ventilator-dependent patients with moderate to severe acute respiratory distress syndrome due to COVID-19 had also not achieved its objectives. Remestemcel-L had not proven to be as effective in preventing death as it was predicted to be.

The company stated the failed remestemcel-L trial was due to improvements in other COVID-19 treatments having been made in the time between gathering the initial pilot data and the execution of the trial. Though, this reasoning didn’t save the company’s share price which fell another 10% in the days following the news.

Compared to 2020, Mesoblast shares appeared to have been pushing through 2021 comparatively stably and even slowly gaining. That was, until the beginning of March.

On 2 March, Mesoblast exited a trading halt by announcing a US$110 million private placement led by a strategic investor group. By 9 March, the Mesoblast share price had plunged nearly 6%.

The company’s shares have since increased slightly but are still 2.85% lower than their final day of trading in February.

Mesoblast is a rare dual listed company

A company gains several benefits from being listed on two separate global exchanges. These include access to greater capital, additional liquidity and more diverse trading hours.

Because Mesoblast’s shares are dual-listed on the ASX and Nasdaq, the company can theoretically action more capital raises with fewer negative consequences, therefore having greater access to additional cash when needed.

Up and coming products

Mesoblast currently has three products at phase 3 trial stage.

They are:

  • Remestemcel-L for the treatment of steroid-refractory acute graft versus host disease and for acute respiratory distress syndrome as a result of COVID-19.
  • REVASCOR for advanced chronic heart failure.
  • MPC-06-ID for lower back pain due to degenerative disc disease.

Mesoblast share price snapshot

Despite a number of significant hits to the Mesoblast share price, it is still trading above its 2021 opening price, currently by around 6%.

The company’s shares are also up an impressive 101% over the last 12 months. So, investors who got in before Mesoblast’s rollercoaster will still be happy with their investment.

Mesoblast has a market capitalisation of $1.6 billion, with approximately 648 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post What’s up with the Mesoblast (ASX:MSB) share price? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!